Soluble ACE2 has been investigated as a potential therapeutic, acting as a competitive interceptor of SARS‐CoV‐2 and preventing viral binding to cells.[20] Recent studies have shown that human recombinant soluble ACE2 (hrsACE2) have shown promise for treating severe COVID‐19.[21, 22]. This evidence concerns the gene ACE2 and COVID-19.